Form 4: Director James Mulay Executes CG Oncology Stock Options

Director James Mulay exercised stock options and sold the resulting shares of CG Oncology, Inc. under a 10b5-1 plan.

Summary

• Director James Mulay exercised options for 654 shares at $3.72 and 1,310 shares at $12.59.
• All acquired shares were immediately sold at a market price of $60.12 per share.
• The transactions were executed on June 15, 2026, pursuant to a Rule 10b5-1 trading plan adopted on March 27, 2026.
• Following these transactions, the director holds 2,620 remaining derivative securities (options) and zero direct shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction was pre-planned and represents standard portfolio management by an insider.

Positives

• Transactions were conducted under a pre-established Rule 10b5-1 trading plan, indicating systematic rather than reactive selling.

Negatives

• The director liquidated their entire direct holding of common stock acquired through these specific option exercises.

Risks

• Future share price volatility may impact the value of remaining unexercised options.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is standard practice for corporate directors and typically does not signal a lack of confidence in the company's long-term prospects.

Comparison to Industry Standards

• The use of 10b5-1 plans is a standard governance practice for executives and directors in the biotechnology sector to avoid potential conflicts of interest regarding material non-public information.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was pre-planned and executed at market value.

Next Steps

• No further actions mentioned.

Key Dates

Keywords

CG Oncology, CGON, Insider Trading, Form 4, Stock Options, Director Transaction